Malaria Transmission Biology

Our research has led to the discovery of a mosquito-based malaria transmission-blocking vaccine (TBV) candidate (the AnAPN1 TBV), which has recently completed process development studies and is under consideration for First-In-Human trials in the near future.  
[Pictured:  Plasmodium falciparum male gamete "exflagellating"]

Learn more

AnAPN1 Vaccine

It has been estimated that more than 1-2 million individuals succumb to Malaria every year, a majority of whom are children under the age of five. Plasmodium parasites, the causative agent of malaria, are transmitted to a vertebrate host by the infective bite of an Anopheles mosquito.
[Pictured: AnAPN1 antigen's N-terminal region depicting key antibody epitopes in purple, green, blue and red]

Learn more

Saliva-based Rapid Diagnostic Tests

Despite widespread malaria control efforts, residual malaria transmission continues to be observed, calling in to question whether the global malaria elimination goals can actually be achieved. A large proportion of this residual malaria parasite transmission is due to low numbers of parasites that cannot be detected by available blood-based rapid diagnostic tests (RDTs) or microscopy.
[Pictured: schematic of the saliva collection process]

Learn more

Arbovirus Transmission Biology

 We conduct both basic and applied research studies in the context of understanding mosquito-transmitted arbovirus transmission biology. This research includes viral pathogen surveillance in mosquitoes and ticks, Florida-relevant vector competence studies, insect-specific virus acquisition modes, as well as mosquito immunology and viral infection dynamics.
[Pictured: Aedes aegypti biting a finger. Image by Sean McCann]

Learn more

Latest News

Stay Up To Date With Our Latest News. Learn About New Developments, Treatments, Vaccines, Our Lab & Much More!
First in human clinical trials of the AnAPN1 malaria transmission-blocking vaccine

Former director of the PATH Malaria Vaccine Initiative, Christian Loucq, M.D., says it is exciting to see Dinglasan's concept moving toward a clinical trial. "There are very interesting issues to be addressed in this project which span the technical, immunological, strategic, regulatory and behavioral," says Dr. Loucq, who also formerly directed the International Vaccine Institute. "A transmission-blocking vaccine would be the most elegant solution to the problem of malaria."

Clustered rapid induction of apoptosis limits ZIKV and DENV-2 proliferation in the midguts of Aedes aegypti

Jasmine's 1st first-author paper (Yay Jasmine!) that dissects very early innate immune defense mechanisms of mosquito vectors following infection with flaviviruses.

UF Professor of Infectious Diseases, Dr. Rhoel Dinglasan, discusses the new saliva COVID tests